PBMC

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Retrieved on: 
Dienstag, Mai 14, 2024
Economics, Immunotherapy, PBMC, Society, CELU, Cell, Journal, Placenta, B cell, Mobile phone

The data compared CAR-T cells derived from Celularity’s proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs).

Key Points: 
  • The data compared CAR-T cells derived from Celularity’s proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs).
  • CAR-T cells generated from its T-Cell platform retained stemness, maintained longer telomeres, and were more resistant to both exhaustion and immune checkpoint upregulation.
  • Moreover, we believe that our placental platform offers a level of scalability and consistency in manufacturing which can significantly impact the economics of delivering these therapies in the future.
  • Through our state-of-the-art manufacturing and technical infrastructure, Celularity can be an ideal development and manufacturing partner in the cellular medicine industry."

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Retrieved on: 
Dienstag, Mai 7, 2024
Microsoft Exchange Server, Cell, MSC, Research, PBMC, Gene, Applied mathematics, Society, IPSC, ERNA, Inflammation, Stem cell, Sclerosis, IDO1, Cell therapy, Silk

While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses.

Key Points: 
  • While mesenchymal stem cells (MSCs) have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses.
  • This variability is often attributed to donor and source heterogeneity and limited expansion potential.
  • Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune cells, which can also contribute to deficient therapeutic responses.
  • Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) promise to directly address many of the fundamental challenges facing MSC translation.

Pixelgen Technologies Announces Peer-Review Publication on Molecular Pixelation Technology in Nature Methods

Retrieved on: 
Mittwoch, Mai 8, 2024
Royal Society Te Apārangi, Karolinska Institute, Cancer, Protein, MPX, Cell, Pixelation, Proteomics, MD, AOCS, Doctor of Philosophy, Research, Imperial College London, DNA, PBMC, Light, Spatial analysis, Microscopy, Messenger, Paper, B cell, Immobilization, NK, Royal institute, Monocyte, Flow cytometry, Vaccine

STOCKHOLM, May 8, 2024 /PRNewswire/ -- Pixelgen Technologies, a leader in spatial proteomics for single cells, announced today that researchers from Pixelgen, the Karolinska Institute, Imperial College of London, and the Royal Institute of Technology in Sweden have demonstrated a ground-breaking sequencing-based method for identifying the relative locations of highly-multiplexed immunologically relevant proteins in single cells, in a peer-reviewed article published in Nature Methods. The Molecular Pixelation (MPX) technology used in the study is the first to demonstrate spatial proteomics of single cells without light, enabling multiplexing, throughput, and spatial resolution in 3D for proteomics-level single cell research.

Key Points: 
  • The Molecular Pixelation (MPX) technology used in the study is the first to demonstrate spatial proteomics of single cells without light, enabling multiplexing, throughput, and spatial resolution in 3D for proteomics-level single cell research.
  • The study, titled "Molecular Pixelation: Spatial Proteomics of single cells by sequencing," illustrates the ability of a DNA-barcode-based strategy to identify and visualize in 3D the spatial protein organization of immune cell receptors.
  • How immune cell surface receptors are organized relative to each other, and their behavior control many of a cell's vital functions.
  • Researchers have traditionally studied spatial surface protein organization with microscopy, using fluorophore-labeled antibodies on immobilized samples or with flow cytometry.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Mittwoch, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Montag, April 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Freitag, April 5, 2024
23andMe, Prevalence, Plasma, Genetics, NKG2D, Patient, SAN, Neoplasm, Data, Endothelium, Immunodeficiency, Cancer, Adenocarcinoma, PBMC, Biology, CD200, AACR, Therapy, Immunohistochemistry, NK, Carcinoma, The Cancer Genome Atlas, PD-1, Vaccine

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.

Key Points: 
  • Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.
  • ULBP6 is a stress-induced ligand that is upregulated on the surface of cancer cells and binds to the activating immunoreceptor NKG2D found on NK and T cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

Retrieved on: 
Montag, März 18, 2024
Notifiable disease, Interest, Cell, Immunotherapy, Patient, CGMP, Travel, Good manufacturing practice, Microsoft Exchange Server, Cancer, Stem cell, PBMC, Life, Shareholder, Infection, Regenerative medicine, Person, Cryopreservation, Collection, Blood, Security (finance)

Recent advances in cell science and technology have enabled researchers to produce specialized cellular therapies from PBMCs.

Key Points: 
  • Recent advances in cell science and technology have enabled researchers to produce specialized cellular therapies from PBMCs.
  • In most cell therapies, using matched donor cells (allogeneic) is required to minimize transplant rejection and maximize therapeutic efficacy.
  • Hence, banking one’s own PBMCs provides a valuable matched cell source for the individual’s own future medical needs.
  • Number of Qualified Shareholders: The Program will be limited to 200 Qualified Shareholders on a first come first served basis.

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Retrieved on: 
Donnerstag, März 14, 2024
Lung cancer, TME, 5T4, Assistant, Patient, Lung, Tumor microenvironment, PM, PBMC, CD3, Neoplasm, NK, Escape Room, Drug resistance, PDE, Vaccine

REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.

Key Points: 
  • REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
  • “Our tribody platform is differentiated with its dual engagers including its NK cell engager having a dual mechanism of action, in addition to the conditionally activated T cell engager.
  • We are excited about the potential of this platform to produce a pipeline of promising drug candidates that can be effective across numerous solid cancer tumors,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • Purple Biotech’s cleavable capping technology confines the compound’s therapeutic activity to the local tumor micro environment (TME), which increases the anticipated therapeutic window in patients.

JGIF: Solving Global Social Challenges Showcasing Japan's Start-ups to the World

Retrieved on: 
Montag, März 11, 2024
Central European, Yūrakuchō Station, Central European Time, Diplomatic mission, Commentator, Silver, Byte, PBMC, Sector, Commerce, Snack, Multimedia, Physical, Flour

Participating Commentators' Countries of Origin: Spain, Germany, the Netherlands, USA, Japan, among others.

Key Points: 
  • Participating Commentators' Countries of Origin: Spain, Germany, the Netherlands, USA, Japan, among others.
  • Tickets: ¥1,500 for on-site participants (includes snacks and drinks for networking event); free for online participants.
  • Topic: How Can Social Innovators in Japan Shine on a Global Stage?
  • - Exploring Japan as a Pioneer Nation in Global Challenges: Unveiling the Sectors Capturing Worldwide Interest
    Light refreshments and soft drinks will be served, and participants will have an opportunity to chat with each other.

A new global startup event in Tokyo offers a chance for Japanese innovators to speak to international audiences - and get their overseas expansion plans assessed

Retrieved on: 
Donnerstag, Februar 29, 2024
PBMC, Silver, Telefónica, Multimedia, Physical, Growth, Commerce, ESG, Government, VCS, Primary energy, Feedback, Snack, Central European, Diplomatic mission, Non-governmental organization, Commentator, Maeda, Heart, Byte, Yūrakuchō Station, Central European Time, Video game

TOKYO, Feb. 29, 2024 /PRNewswire/ -- Representatives of innovative Japanese startups with global ambitions will be gathering in the heart of Tokyo on March 15. They will showcase the solutions they offer to help solve the world's biggest social and environmental challenges. A panel of international experts will assess their growth potential overseas.

Key Points: 
  • The inaugural Japan Global Innovators' Forum (JGIF) will invite promising Japanese startups from three specific categories: Age Tech, Disaster Tech, and Clean Energy.
  • Various industry experts, ranging from venture capitalists to media professionals and international NGOs, will provide the Japanese innovators with hands-on feedback and advice on their global expansion plans.
  • The event can also serve as an opportunity for overseas journalists to directly cover Japanese startups and innovators.
  • "Driven by such awareness, we have organized this event to support the global outreach of promising Japanese startups," said Maeda.